Combo bests standard care in younger CLL patients

Print Friendly, PDF & Email


2018 ASH Annual Meeting
©ASH/Scott Morgan 2018
In a phase 3 trial, ibrutinib plus rituximab (IR) improved survival when compared with standard chemoimmunotherapy in patients younger than 70 with untreated chronic lymphocytic leukemia (CLL). Patients who received IR had superior progression-free survival (PFS) and overall survival compared to patients who received fludarabine, cyclophosphamide, and rituximab... [Read Article]
Print Friendly, PDF & Email

Fludarabine deemed important for CD30.CAR T-cell therapy

Print Friendly, PDF & Email


Attendees at ASH 2018
Photo courtesy of ASH
Fludarabine is “very important” for lymphodepletion prior to CD30-directed chimeric antigen receptor (CAR) T-cell therapy, according to a presentation at the 2018 ASH Annual Meeting. A phase 1/2 study showed that bendamustine alone was not sufficient as lymphodepletion. However, adding fludarabine to bendamustine could enhance responses... [Read Article]
Print Friendly, PDF & Email

Shorter R-CHOP regimen noninferior in certain DLBCL patients

Print Friendly, PDF & Email


Viola Poeschel, MD
© ASH/Scott Morgan 2018
A shortened regimen of four cycles of rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy was noninferior in efficacy to the standard six cycles of R-CHOP in younger patients with favorable-risk diffuse large B-cell lymphoma (DLBCL), according to investigators of the FLYER trial. In addition,... [Read Article]
Print Friendly, PDF & Email

Regimen provides survival benefit in PTCL

Print Friendly, PDF & Email


Attendees at ASH 2018
Photo courtesy of ASH
A newly approved treatment regimen provides a survival benefit over standard therapy for patients with CD30-positive peripheral T-cell lymphomas (PTCLs), according to a presentation at the 2018 ASH Annual Meeting. In the ECHELON-2 trial, patients who received brentuximab vedotin (BV) plus cyclophosphamide, doxorubicin, and prednisone (CHP) had... [Read Article]
Print Friendly, PDF & Email

New PCNSL guidelines emphasize importance of patient fitness

Print Friendly, PDF & Email


Micrograph showing PCNSL
Image by Michael Bonert
New guidelines on the diagnosis and management of patients with primary central nervous system lymphoma (PCNSL) emphasize prompt diagnosis, aggressive treatment whenever possible, and multidisciplinary team support. A unique aspect for hematologic cancers, the guideline authors wrote, is that appropriate treatment requires input from neurology specialists. And they... [Read Article]
Print Friendly, PDF & Email

EC approves mogamulizumab for MF, SS

Print Friendly, PDF & Email


Micrograph showing
mycosis fungoides
The European Commission (EC) has granted marketing authorization for mogamulizumab (Poteligeo), a humanized monoclonal antibody directed against CCR4. This means mogamulizumab is approved for use in adults with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. This approval is valid in all... [Read Article]
Print Friendly, PDF & Email

Biosimilar deemed equivalent to rituximab in FL

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
Phase 3 results suggest the biosimilar product CT-P10 is equivalent to rituximab in patients with low-tumor-burden follicular lymphoma (FL). Overall response rates were similar—both exceeding 80%—in patients who received CT-P10 and those who received rituximab. In addition, adverse event (AE) profiles were comparable between the treatment arms.... [Read Article]
Print Friendly, PDF & Email

Bortezomib may overcome resistance in WM

Print Friendly, PDF & Email


Micrograph showing
Waldenström’s macroglobulinemia
Image from Michail Charakidis
and David Joseph Russell
Bortezomib may help overcome treatment resistance in patients with Waldenström’s macroglobulinemia (WM) and CXCR4 mutations, according to a new study. Researchers assessed the impact of treatment with bortezomib and rituximab in patients with WM, based on their CXCR4 mutation status. The team... [Read Article]
Print Friendly, PDF & Email